BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38298193)

  • 1. Refining patient selection for next-generation immunotherapeutic early-phase clinical trials with a novel and externally validated prognostic nomogram.
    Losurdo A; Dipasquale A; Giordano L; Persico P; Lorenzi E; Di Muzio A; Barigazzi C; Korolewicz J; Mehan A; Mohammed O; Scheiner B; Pinato DJ; Santoro A; Simonelli M
    Front Immunol; 2024; 15():1323151. PubMed ID: 38298193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).
    Bigot F; Castanon E; Baldini C; Hollebecque A; Carmona A; Postel-Vinay S; Angevin E; Armand JP; Ribrag V; Aspeslagh S; Varga A; Bahleda R; Menis J; Gazzah A; Michot JM; Marabelle A; Soria JC; Massard C
    Eur J Cancer; 2017 Oct; 84():212-218. PubMed ID: 28826074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
    Zhu J; Li R; Tiselius E; Roudi R; Teghararian O; Suo C; Song H
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011300. PubMed ID: 29247502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab.
    Botticelli A; Salati M; Di Pietro FR; Strigari L; Cerbelli B; Zizzari IG; Giusti R; Mazzotta M; Mazzuca F; Roberto M; Vici P; Pizzuti L; Nuti M; Marchetti P
    J Transl Med; 2019 Mar; 17(1):99. PubMed ID: 30917841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
    Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
    Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
    [No Abstract]   [Full Text] [Related]  

  • 6. Identification of prognostic factors and nomogram model for patients with advanced lung cancer receiving immune checkpoint inhibitors.
    Chen X; Li Z; Zhou J; Wei Q; Wang X; Jiang R
    PeerJ; 2022; 10():e14566. PubMed ID: 36540802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the effectiveness of chemotherapy combined with immunotherapy and chemotherapy alone in advanced biliary tract cancer and construction of the nomogram for survival prediction based on the inflammatory index and controlling nutritional status score.
    Zhang Z; Wang D; Zhang J; Ruan Y; Zhao L; Yang L; Liu Z; Yang L; Lou C
    Cancer Immunol Immunother; 2023 Nov; 72(11):3635-3649. PubMed ID: 37668711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).
    Necchi A; Sonpavde G; Lo Vullo S; Giardiello D; Bamias A; Crabb SJ; Harshman LC; Bellmunt J; De Giorgi U; Sternberg CN; Cerbone L; Ladoire S; Wong YN; Yu EY; Chowdhury S; Niegisch G; Srinivas S; Vaishampayan UN; Pal SK; Agarwal N; Alva A; Baniel J; Golshayan AR; Morales-Barrera R; Bowles DW; Milowsky MI; Theodore C; Berthold DR; Daugaard G; Sridhar SS; Powles T; Rosenberg JE; Galsky MD; Mariani L;
    Eur Urol; 2017 Feb; 71(2):281-289. PubMed ID: 27726966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pretreatment Blood Parameters Predict Efficacy from Immunotherapy Agents in Early Phase Clinical Trials.
    Criscitiello C; Marra A; Morganti S; Zagami P; Viale G; Esposito A; Curigliano G
    Oncologist; 2020 Nov; 25(11):e1732-e1742. PubMed ID: 32785940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting Overall Survival After Stereotactic Ablative Radiation Therapy in Early-Stage Lung Cancer: Development and External Validation of the Amsterdam Prognostic Model.
    Louie AV; Haasbeek CJ; Mokhles S; Rodrigues GB; Stephans KL; Lagerwaard FJ; Palma DA; Videtic GM; Warner A; Takkenberg JJ; Reddy CA; Maat AP; Woody NM; Slotman BJ; Senan S
    Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):82-90. PubMed ID: 26138912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Establishment and validation of a novel nomogram to predict overall survival after radical nephrectomy].
    Xiong LB; Zou XP; Ning K; Luo X; Peng YL; Zhou ZH; Wang J; Li Z; Yu CP; Dong P; Guo SJ; Han H; Zhou FJ; Zhang ZL
    Zhonghua Zhong Liu Za Zhi; 2023 Aug; 45(8):681-689. PubMed ID: 37580273
    [No Abstract]   [Full Text] [Related]  

  • 13. Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy.
    Buti S; Bersanelli M; Perrone F; Bracarda S; Di Maio M; Giusti R; Nigro O; Cortinovis DL; Aerts JGJV; Guaitoli G; Barbieri F; Ferrara MG; Bria E; Grossi F; Bareggi C; Berardi R; Torniai M; Cantini L; Sforza V; Genova C; Chiari R; Rocco D; Della Gravara L; Gori S; De Tursi M; Di Marino P; Mansueto G; Zoratto F; Filetti M; Citarella F; Russano M; Mazzoni F; Garassino MC; De Toma A; Signorelli D; Gelibter A; Siringo M; Follador A; Bisonni R; Tuzi A; Minuti G; Landi L; Ricciardi S; Migliorino MR; Tabbò F; Olmetto E; Metro G; Adamo V; Russo A; Spinelli GP; Banna GL; Addeo A; Friedlaender A; Cannita K; Porzio G; Ficorella C; Carmisciano L; Pinato DJ; Mazzaschi G; Tiseo M; Cortellini A
    Eur J Cancer; 2021 Jun; 150():224-231. PubMed ID: 33934059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A nomogram model based on the number of examined lymph nodes-related signature to predict prognosis and guide clinical therapy in gastric cancer.
    Li H; Lin D; Yu Z; Li H; Zhao S; Hainisayimu T; Liu L; Wang K
    Front Immunol; 2022; 13():947802. PubMed ID: 36405735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials.
    Alhalabi O; Hahn AW; Msaouel P; Meric-Bernstam F; Wilson N; Naing A; Piha-Paul S; Janku F; Pant S; Yap TA; Hong DS; Fu S; Karp D; Beltran K; Campbell E; Le H; Campbell MT; Shah A; Tannir NM; Siefker-Radtke A; Gao J; Roszik J; Subbiah V
    Clin Genitourin Cancer; 2022 Feb; 20(1):e16-e24. PubMed ID: 34362693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and Validation of a Tumor Microenvironment-Related Gene Signature for Prognostic Prediction in Advanced-Stage Non-Small-Cell Lung Cancer.
    Zhang X; Shi X; Zhao H; Jia X; Yang Y
    Biomed Res Int; 2021; 2021():8864436. PubMed ID: 33860055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction and validation of prognostic nomograms for elderly patients with metastatic non-small cell lung cancer.
    Sun H; Liu M; Yang X; Ren Y; Dai H; Wang C
    Clin Respir J; 2022 May; 16(5):380-393. PubMed ID: 35514033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External Validation.
    Prelaj A; Lo Russo G; Proto C; Signorelli D; Ferrara R; Galli G; De Toma A; Randon G; Pagani F; Trevisan B; Ganzinelli M; Zilembo N; Montrone M; Longo V; Pesola F; Pizzutilo P; Del Bene G; Varesano N; Galetta D; Torri V; Garassino MC; Di Maio M; Catino A
    Clin Lung Cancer; 2020 Sep; 21(5):e337-e348. PubMed ID: 32291212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nomograms for predicting disease progression in patients of Stage I non-small cell lung cancer treated with stereotactic body radiotherapy.
    Ye L; Shi S; Zeng Z; Huang Y; Hu Y; He J
    Jpn J Clin Oncol; 2018 Feb; 48(2):160-166. PubMed ID: 29253245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishment and Validation of a Nomogram Based on Negative Lymph Nodes to Predict Survival in Postoperative Patients with non-Small Cell Lung Cancer.
    Huang X; Hu P; Yan F; Zhang J
    Technol Cancer Res Treat; 2022; 21():15330338221074506. PubMed ID: 35060800
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.